NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Packaged Foods · USD

Clene Inc. (CLNN) Stock Analysis

Clene Inc. (CLNN) is a Packaged Foods stock listed on NASDAQ and quoted in US Dollar.

CLNN

$3.85

−$0.15 (−3.75%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare CLNN with… →

CLNN Key Statistics

As of Sep 4, 2026
Trading
Open
$3.92
Previous Close
$4.00
Day's Range
3.72–4.00
52-Week Range
3.72–13.50
Volume
122.60K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.95
Valuation
Market Cap
$49.47M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
251.10
EPS (ttm)Profit attributable to each share over the last twelve months.
−3.49
Financials (FY)
Revenue (FY)
$200.00K−41.52%
Net Income (FY)
−$26.17M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
12.85M
1-Year Return
−35.29%
Dividend and dates
Avg Volume
79.67K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

CLNN Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−34.41%
2025+10.55%
2024−11.50%
2023−70.00%
2022−75.61%
2021−62.11%
2020+3.24%
2019+5.86%
2018 (partial year)+1.54%

As of September 4, 2026.

CLNN Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$200.00K−$26.17M−13086.5%
2024$342.00K−$39.40M−11520.5%
2023$654.00K−$49.50M−7569.4%
2022$473.00K−$29.92M−6325.2%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$200.00K$157.00K−$21.82M−$26.17M−13086.5%
2024$342.00K$272.00K−$31.98M−$39.40M−11520.5%
2023$654.00K$533.00K−$38.26M−$49.50M−7569.4%
2022$473.00K$447.00K−$44.56M−$29.92M−6325.2%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

CLNN Valuation vs Packaged Foods Median

Median of 76 stocks
MetricCLNNPackaged Foods medianvs median
P/S ratio251.100.65386.7x the median
Profit margin0.00%0.50%0.5 pts below

Medians across 76 Packaged Foods stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Analysis

Data-derived

Company Overview

Clene Inc. (CLNN) carries a market capitalisation of $49.47M. It is classified in the Packaged Foods industry, within the Consumer Defensive sector. Headcount on file is 76.

Over the past 52 weeks the price has ranged from $3.72 to $13.50. The most recent close on file for CLNN is $3.85, dated September 4, 2026. That is −$0.15 (−3.75%) against the previous close. The latest close sits 3.49% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $200.00K. That is −41.52% against the prior fiscal year, when revenue was $342.00K. The same year closed with a net loss of $26.17M. The reported profit margin is 0%. That is 0.5 percentage points below the Packaged Foods median of 0.5%. Trailing earnings per share are −3.49.

Across the 4 fiscal years on file, revenue moves from $473.00K in 2022 to $200.00K in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. The price-to-sales ratio is 251.1. On price-to-sales that is 386.7 times the Packaged Foods median of 0.65. The medians here are taken across 76 Packaged Foods companies that report the metric.

The reported beta is 0.95. Annualized volatility over the trailing 7 years is 100.8%. Over the trailing twelve months the price has returned −35.29%. Across 5 years the annualized return works out at −52.64%.

Growth & Income

No dividend is on file for CLNN.

Across the complete calendar years on file, 2025 returned +10.55% and 2022 returned −75.61%. Of the 7 complete calendar years on file, 3 finished higher. So far in 2026 the price is −34.41%.

Peer Comparison

Clene Inc. (CLNN) operates in the Packaged Foods industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Clene Inc. CLNN $49.47M —
The Kraft Heinz Company KHC $29.47B —
General Mills, Inc. GIS $20.47B —
Saputo Inc. SAP.TO $15.93B 23.1

The Packaged Foods industry average P/E ratio is 15.5x. Clene Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Packaged Foods Stocks

KHC

The Kraft Heinz Company

$29.47B

 GIS

General Mills, Inc.

$20.47B

 SAP.TO

Saputo Inc.

$15.93B

 MKC

McCormick & Company, Incorporated

$14.00B

 JBS

JBS N.V.

$13.95B

 SJM

The J. M. Smucker Company

$13.47B
View all Packaged Foods stocks →

Popular Consumer Defensive Stocks

WMT

Walmart Inc.

$852.63B

 COST

Costco Wholesale Corporation

$406.11B

 KO

The Coca-Cola Company

$378.93B

 PG

The Procter & Gamble Company

$340.13B

 PM

Philip Morris International Inc.

$284.49B
View all Consumer Defensive stocks →

About Clene Inc.

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. The company's lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. It develops CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease and to provide immune support for symptom resolution. In addition, the company markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. Clene Inc. is headquartered in Salt Lake City, Utah.

Visit website →